310 related articles for article (PubMed ID: 32462251)
1. [Tumor vaccines-therapeutic vaccination against cancer].
Rammensee HG; Löffler MW; Walz JS; Bokemeyer C; Haen SP; Gouttefangeas C
Internist (Berl); 2020 Jul; 61(7):690-698. PubMed ID: 32462251
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
3. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
4. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccination progress.
Pawelec G; Rees RC
Trends Mol Med; 2002 Dec; 8(12):545-6. PubMed ID: 12470983
[TBL] [Abstract][Full Text] [Related]
6. Peptide-based cancer vaccines.
Machiels JP; van Baren N; Marchand M
Semin Oncol; 2002 Oct; 29(5):494-502. PubMed ID: 12407514
[TBL] [Abstract][Full Text] [Related]
7. Melanoma peptide vaccines: from preclinical background to clinical trials.
Weber J
Curr Oncol Rep; 2000 Jan; 2(1):38-47. PubMed ID: 11122823
[TBL] [Abstract][Full Text] [Related]
8. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
9. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
10. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
11. Melanoma antigens and targets for vaccination.
Kang N; Truman H; Sanders R; Kupsch J
Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.
Burdin N; Moingeon P
Cell Biol Toxicol; 2001; 17(2):67-75. PubMed ID: 11499697
[TBL] [Abstract][Full Text] [Related]
13. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
14. T-cell-directed cancer vaccines: the melanoma model.
Wang E; Phan GQ; Marincola FM
Expert Opin Biol Ther; 2001 Mar; 1(2):277-90. PubMed ID: 11727535
[TBL] [Abstract][Full Text] [Related]
15. Vaccination for malignant melanoma: recent developments.
Jäger D; Jäger E; Knuth A
Oncology; 2001; 60(1):1-7. PubMed ID: 11150901
[TBL] [Abstract][Full Text] [Related]
16. Melanoma vaccines: prim and proper presentation.
Timmerman JM; Levy R
Nat Med; 1998 Mar; 4(3):269-70. PubMed ID: 9500593
[No Abstract] [Full Text] [Related]
17. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
18. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
19. Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I.
Quatan N; Spicer J; Plunkett T; Pandha H
Clin Oncol (R Coll Radiol); 2004 Aug; 16(5):356-65. PubMed ID: 15341440
[No Abstract] [Full Text] [Related]
20. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
Germeau C; Ma W; Schiavetti F; Lurquin C; Henry E; Vigneron N; Brasseur F; Lethé B; De Plaen E; Velu T; Boon T; Coulie PG
J Exp Med; 2005 Jan; 201(2):241-8. PubMed ID: 15657293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
